#United States #Boehringer Ingelheim #Orsini #JASCAYD® #Elk Grove Village, Illinois

Orsini's Partnership with Boehringer Ingelheim for JASCAYD®

In a notable development for the treatment of idiopathic pulmonary fibrosis (IPF), Orsini, a leader in rare disease pharmacy services, has officially partnered with Boehringer Ingelheim as a specialty pharmacy provider for JASCAYD® (nerandomilast). This marked a significant addition to Orsini's offerings, reinforcing their commitment to supporting those affected by rare diseases.

Understanding JASCAYD® and IPF

JASCAYD® is an FDA-approved oral medication designed specifically for adult patients with idiopathic pulmonary fibrosis, a progressively debilitating lung condition characterized by the thickening and scarring of lung tissue. As the disease progresses, patients often grapple with severe symptoms including persistent dry cough, shortness of breath, fatigue, significant weight loss, and muscle and joint pain. The introduction of JASCAYD® aims to slow the decline in lung function for these patients, offering them hope for managing their condition more effectively.

In a statement regarding this partnership, Orsini’s CEO Brandon Tom expressed pride in the longstanding relationship with Boehringer Ingelheim, highlighting the organization's extensive experience in the IPF space, serving over 6,000 patients. This partnership is not just about providing a new therapy; it reflects a continued dedication to enhancing patient care and expanding the options available for those living with IPF.

Orsini's Approach to Patient Care

Since its inception in 1987, Orsini has prioritized compassionate care and comprehensive support for patients facing rare diseases and complex treatments. The organization collaborates closely with biopharma innovators, healthcare providers, and payors to ensure that patients can access groundbreaking therapies like JASCAYD® seamlessly. Moreover, Orsini’s innovative care model includes pharmacy distribution, clinical management, and home infusion services, making advanced treatments more accessible for patients.

Their high-touch approach involves experienced therapy care teams who provide tailored patient care, embodying the motto, "No Patient is Left Behind™." Furthermore, Orsini's accreditations from reputable bodies such as the Accreditation Commission for Health Care (ACHC), The Joint Commission, URAC, and NABP validate their commitment to quality and regulatory excellence. The company has also achieved URAC’s Rare Disease Pharmacy Center of Excellence Designation and ACHC’s Distinction in Rare Diseases and Orphan Drugs, indicating their leadership in this critical field.

The Future of Rare Disease Treatment

The announcement of this partnership arrives at a time when the importance of specialized care in the treatment of rare diseases is more important than ever. With each new therapy, the potential for improving the quality of life for those affected by challenging health conditions grows. Orsini’s ongoing collaboration with Boehringer Ingelheim is a testament to the advancements being made in this space, and the positive outcomes that can be achieved when organizations work in tandem towards a common goal.

As they look forward, both Orsini and Boehringer Ingelheim are committed to improving patient outcomes through innovative therapies and dedicated patient support—a pledge that sets a foundation for growth and progress in the future of rare disease treatment. For further information on Orsini and their services, visiting their official website at www.orsini.com is encouraged.